Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
Hims & Hers Health, Inc. filed an initial Form 3 for board member Amoo-Gottfried Kofi Owusu, indicating his status as a director but not as an officer or ten percent owner. The filing does not report any insider transactions or derivative positions and serves mainly as an initial ownership disclosure.
Hims & Hers Health, Inc. director Christopher D. Payne exercised restricted stock unit awards into a total of 14,343 shares of Class A Common Stock in June 2026, all at a price of $0.00 per share. These are compensation-related derivative exercises rather than open‑market purchases or sales.
After the transactions, he holds 34,318 shares directly and 110,000 shares indirectly through The Payne Family Trust dated September 17, 2020. Some RSUs remain outstanding, including 10,040 units granted in lieu of $14,875 of first‑quarter 2026 director and committee cash fees, calculated at a grant price of $22.98 per share and scheduled to vest on the company’s next quarterly vesting date.
Hims & Hers Health, Inc. director Christiane Pendarvis exercised previously granted Restricted Stock Units (RSUs), converting 3,656 RSUs into an equal number of Class A Common shares at a stated price of $0.00 per share. Following this transaction, she directly holds 55,430 Class A Common shares.
The RSUs represent a contingent right to receive one share of Class A Common Stock for each unit and will vest, subject to continuous service, on the earlier of the company’s 2026 annual meeting of stockholders or June 15, 2026. This is a compensation-related, non‑open‑market equity award rather than a market purchase or sale.
Hims & Hers Health, Inc. director Manuel Anja reported equity compensation activity involving Restricted Stock Units (RSUs) that convert into Class A Common Stock. On June 11, 2026, RSU vesting and exercise resulted in the acquisition of 3,656 shares of Class A Common Stock at a stated price of $0.0000 per share, increasing his direct holdings to 28,631 shares.
On June 15, 2026, additional RSUs were exercised for 10,040 shares of Class A Common Stock, again at a stated price of $0.0000 per share, bringing his direct ownership to 38,671 shares. The footnotes explain that each RSU is a contingent right to receive one share of Class A Common Stock, subject to continuous service and service-based vesting schedules through dates including June 15, 2025, June 15, 2026, and May 15, 2027.
Hims & Hers Health, Inc. director Delos M. Cosgrove reported a compensation-related equity transaction involving restricted stock units. On June 11, 2026, he exercised RSUs covering 3,656 shares of Class A Common Stock, converting them from derivative form into common shares.
Following this RSU conversion, Cosgrove directly holds 67,995 shares of Class A Common Stock. The RSUs represent a contingent right to receive one share of Class A Common Stock for each unit and, subject to continuous service, will vest on the earlier of the company’s 2026 annual stockholders’ meeting or June 15, 2026.
Hims & Hers Health, Inc. reported the results of its annual stockholder meeting held on June 11, 2026. Stockholders elected nine directors to serve until the 2027 annual meeting, with each nominee receiving over 1.5 billion votes "for" and substantial support.
As of the April 15, 2026 record date, there were 222,525,754 Class A shares and 8,377,623 Class V shares outstanding, with Class A carrying one vote per share and Class V carrying 175 votes per share, voting together as a single class.
Stockholders also ratified the appointment of KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026, with about 1.59 billion votes in favor. In an advisory vote, stockholders approved the Company’s executive compensation with over 1.5 billion votes "for" and a relatively small number of votes against or abstaining.
Hims & Hers Health, Inc. entered into Amendment No. 3 to its Revolving Credit and Guaranty Agreement, mainly to facilitate closing its acquisition of Eucalyptus. The amendment adds a grace period for covenant and representation compliance after the deal, sets joinder obligations for material foreign subsidiaries, and increases downstream investment capacity in non-loan party subsidiaries, while leaving loan amounts, interest terms, fees, covenants and events of default otherwise unchanged.
The company also completed its previously announced acquisition of Eucalyptus, adding a significant international presence across Australia, Canada, Germany, Japan, and the United Kingdom. Eucalyptus has served more than 850,000 customers as of May 2026. Hims & Hers reiterated long-term 2030 targets of $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA.
Hims & Hers Health, Inc. director David B. Wells reported an open-market purchase of Class A Common Stock. On May 26, 2026, he bought 48,400 shares at an average price of $24.235 per share, increasing his direct holdings to 224,417 shares.
The reported purchase price is a weighted average, with individual trades executed between $24.19 and $24.25 per share. Wells conducted these transactions as direct ownership in the company’s Class A Common Stock.
Hims & Hers Health, Inc. director and Chief Medical Officer Patrick Harrison received a grant of 435 Restricted Stock Units as part of his board compensation. The RSUs were issued in lieu of a $10,000 cash retainer for the first quarter of 2026 and convert into Class A Common Stock on vesting. The award will vest in full on the company’s next quarterly vesting date, giving him equity-based compensation instead of cash for that period.
Payne Christopher D reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. director Christopher D. Payne received a grant of 647 Restricted Stock Units as equity compensation. Each RSU represents a contingent right to receive one share of Class A common stock. The award was issued under the company’s Director Compensation Policy.
The RSUs were granted in lieu of $14,875 in director and committee cash fees for the first quarter of 2026, using a grant price of $22.98. All 647 RSUs will vest in full on the company’s next quarterly vesting date, leaving Payne with 647 RSUs reported as directly owned after this transaction.